Rob has managed the design, development, and operations of manufacturing for biologics, vaccines, and gene therapies, making medicines that have changed the lives of millions of patients. Prior to joining Affinia Therapeutics, Rob led the design, build, and operations of a state-of-the-art 170,000-square-foot good manufacturing practice (GMP) grade gene therapy manufacturing plant for clinical and commercial supply at AveXis, where he was vice president, North Carolina site head. Before AveXis, Rob was the U.S. head of technical development operations for Novartis/GSK Vaccines, where he was responsible for the delivery of several viral vaccine development programs using a variety of production platforms. He also spent 17 years on the biologics manufacturing team at Amgen. Rob received a B.A. in biology from the University of California, Berkeley.
Discover what
it’s like to be an Affinian
Changing the world for patients. Powered by science.